Daewoong Pharmaceutical Botulinum Toxin, Enters UK Market

Daewoong Pharmaceutical's botulinum toxin 'Nabota' (UK release name Nuciva)

[Asia Economy Reporter Lee Chun-hee] Daewoong Pharmaceutical announced on the 5th that its botulinum toxin (BTX) ‘Nuceiva (domestic product name Nabota)’ was officially launched in the United Kingdom last month through its partner Evolus.

With this, Daewoong Pharmaceutical has officially entered the European market, the world's second-largest BTX market with an annual size of 650 billion KRW, following the United States. In particular, the UK is the largest single market in Europe, accounting for about 30% of the European BTX market.

Distribution and marketing of Nuceiva in the UK are handled by Evolus, Daewoong Pharmaceutical BTX’s North America and Europe aesthetic indication partner. Ahead of the Nuceiva launch, Evolus established a strategic partnership with Wigmore, a UK-based specialized distributor with over 35 years of history, building a BTX-specialized distribution network and preparing thoroughly. Since early this month, they have also been conducting education on the latest knowledge and Nuceiva products for local medical professionals. Daewoong Pharmaceutical and Evolus plan to expand into other European countries with high market potential such as Germany and Austria, actively targeting the European market.

Park Sung-soo, Vice President of Daewoong Pharmaceutical, said, “With the launch of Nuceiva in the UK, we have officially entered both the US and European markets, which are the first and second largest BTX markets worldwide,” adding, “We will actively promote the excellent product quality of Nabota in the global market and contribute to raising the status of K-bio with a sense of responsibility as a leading BTX brand representing Korea.”

This content was produced with the assistance of AI translation services.